Do analysts prefer LIMN or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, LIMN or QNTM?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.47 N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is LIMN or QNTM more profitable?

Liminatus Pharma's return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% Quantum Biopharma N/A -582.23% -184.20%

Does the media favor LIMN or QNTM?

In the previous week, Liminatus Pharma had 2 more articles in the media than Quantum Biopharma. MarketBeat recorded 6 mentions for Liminatus Pharma and 4 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.47 beat Liminatus Pharma's score of -0.03 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CELU or LIMN?

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 581.51%. Given Celularity's stronger consensus rating and higher probable upside, equities analysts plainly believe Celularity is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELU or LIMN more profitable?

Liminatus Pharma has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Liminatus Pharma N/A N/A -256.58%

Does the media refer more to CELU or LIMN?

In the previous week, Liminatus Pharma had 3 more articles in the media than Celularity. MarketBeat recorded 6 mentions for Liminatus Pharma and 3 mentions for Celularity. Celularity's average media sentiment score of 0.48 beat Liminatus Pharma's score of -0.03 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NEUP or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Liminatus Pharma N/A N/A -256.58%

Does the media refer more to NEUP or LIMN?

In the previous week, Liminatus Pharma had 3 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 6 mentions for Liminatus Pharma and 3 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.96 beat Liminatus Pharma's score of -0.03 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ALVR or LIMN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ALVR or LIMN?

Liminatus Pharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Liminatus Pharma N/A N/A -$10.21M -$0.47 N/A

Is ALVR or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Liminatus Pharma N/A N/A -256.58%

Do analysts recommend HOWL or LIMN?

Werewolf Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 304.53%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HOWL or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -166.99% -59.88% Liminatus Pharma N/A N/A -256.58%

Does the media favor HOWL or LIMN?

In the previous week, Werewolf Therapeutics had 10 more articles in the media than Liminatus Pharma. MarketBeat recorded 16 mentions for Werewolf Therapeutics and 6 mentions for Liminatus Pharma. Werewolf Therapeutics' average media sentiment score of 0.41 beat Liminatus Pharma's score of -0.03 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Liminatus Pharma (LIMN) Competitors

$4.41 -0.20 (-4.34%)

As of 04:00 PM Eastern

Compare

LIMN vs. QNTM, CELU, NEUP, ALVR, and HOWL

Should you buy Liminatus Pharma stock or one of its competitors? Liminatus Pharma's main competitors and comparable companies include Quantum Biopharma (QNTM), Celularity (CELU), Neuphoria Therapeutics (NEUP), AlloVir (ALVR), and Werewolf Therapeutics (HOWL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Liminatus Pharma compare to Quantum Biopharma?

Liminatus Pharma (NASDAQ:LIMN) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Liminatus Pharma has a beta of 5.35, suggesting that its share price is 435% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Liminatus Pharma's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Quantum Biopharma	N/A	-582.23%	-184.20%

Liminatus Pharma is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.47	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Quantum Biopharma shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Liminatus Pharma had 2 more articles in the media than Quantum Biopharma. MarketBeat recorded 6 mentions for Liminatus Pharma and 4 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.47 beat Liminatus Pharma's score of -0.03 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liminatus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Liminatus Pharma beats Quantum Biopharma on 7 of the 10 factors compared between the two stocks.

How does Liminatus Pharma compare to Celularity?

Celularity (NASDAQ:CELU) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Liminatus Pharma has a net margin of 0.00% compared to Celularity's net margin of -345.45%.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Liminatus Pharma	N/A	N/A	-256.58%

Celularity has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.35, meaning that its stock price is 435% more volatile than the broader market.

Liminatus Pharma has lower revenue, but higher earnings than Celularity. Liminatus Pharma is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.96	-$91.72M	-$3.33	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.47	N/A

In the previous week, Liminatus Pharma had 3 more articles in the media than Celularity. MarketBeat recorded 6 mentions for Liminatus Pharma and 3 mentions for Celularity. Celularity's average media sentiment score of 0.48 beat Liminatus Pharma's score of -0.03 indicating that Celularity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liminatus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.0% of Celularity shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Celularity presently has a consensus target price of $6.00, indicating a potential upside of 581.51%. Given Celularity's stronger consensus rating and higher probable upside, equities analysts plainly believe Celularity is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Celularity and Liminatus Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Liminatus Pharma. Liminatus Pharma is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.33	-$370K	-$11.06	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.47	N/A

Neuphoria Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.35, meaning that its stock price is 435% more volatile than the broader market.

Liminatus Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Liminatus Pharma	N/A	N/A	-256.58%

Neuphoria Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 444.04%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Neuphoria Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Liminatus Pharma had 3 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 6 mentions for Liminatus Pharma and 3 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.96 beat Liminatus Pharma's score of -0.03 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liminatus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neuphoria Therapeutics beats Liminatus Pharma on 8 of the 14 factors compared between the two stocks.

How does Liminatus Pharma compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.35, indicating that its stock price is 435% more volatile than the broader market.

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Liminatus Pharma's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Liminatus Pharma	N/A	N/A	-256.58%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Liminatus Pharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.47	N/A

In the previous week, Liminatus Pharma had 6 more articles in the media than AlloVir. MarketBeat recorded 6 mentions for Liminatus Pharma and 0 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 beat Liminatus Pharma's score of -0.03 indicating that AlloVir is being referred to more favorably in the media.

Company	Overall Sentiment
AlloVir	Neutral
Liminatus Pharma	Neutral

Summary

Liminatus Pharma beats AlloVir on 7 of the 11 factors compared between the two stocks.

How does Liminatus Pharma compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Liminatus Pharma has lower revenue, but higher earnings than Werewolf Therapeutics. Liminatus Pharma is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	25.56	-$60.82M	-$0.76	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.47	N/A

Liminatus Pharma's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Liminatus Pharma	N/A	N/A	-256.58%

In the previous week, Werewolf Therapeutics had 10 more articles in the media than Liminatus Pharma. MarketBeat recorded 16 mentions for Werewolf Therapeutics and 6 mentions for Liminatus Pharma. Werewolf Therapeutics' average media sentiment score of 0.41 beat Liminatus Pharma's score of -0.03 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liminatus Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Werewolf Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.35, indicating that its stock price is 435% more volatile than the broader market.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Werewolf Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 304.53%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Werewolf Therapeutics beats Liminatus Pharma on 9 of the 14 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.45M	$4.03B	$7.29B	$12.77B
Dividend Yield	N/A	3.63%	2.53%	10.79%
P/E Ratio	-0.19	11.42	272.49	24.14
Price / Sales	N/A	1,366.62	626.72	98.16
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	14.70	16.87	13.14	6.23
Net Income	-$10.21M	-$22.76M	$3.47B	$348.07M
7 Day Performance	-21.04%	1.54%	1.38%	0.67%
1 Month Performance	-20.47%	11.70%	8.62%	4.84%
1 Year Performance	-97.29%	56.88%	25.90%	16.83%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	0.1912 of 5 stars	$4.41 -4.3%	N/A	-97.3%	$4.45M	N/A	N/A	N/A	Short Interest Increase Gap Down
QNTM Quantum Biopharma	0.798 of 5 stars	$3.47 -1.4%	N/A	-81.5%	$22.21M	N/A	N/A	N/A
CELU Celularity	1.6935 of 5 stars	$0.77 -1.7%	$6.00 +684.3%	-79.1%	$22.15M	$26.55M	N/A	220	News Coverage
NEUP Neuphoria Therapeutics	3.0925 of 5 stars	$3.96 +0.8%	$21.00 +430.3%	-47.4%	$21.38M	$15.65M	N/A	N/A	News Coverage Upcoming Earnings Short Interest Decrease
ALVR AlloVir	N/A	$4.17 +3.5%	N/A	+63.3%	$21.03M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. QNTM, CELU, NEUP, ALVR, and HOWL

How does Liminatus Pharma compare to Quantum Biopharma?

Summary

How does Liminatus Pharma compare to Celularity?

Summary

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Summary

How does Liminatus Pharma compare to AlloVir?

Summary

How does Liminatus Pharma compare to Werewolf Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. QNTM, CELU, NEUP, ALVR, and HOWL

How does Liminatus Pharma compare to Quantum Biopharma?

Which has more risk & volatility, LIMN or QNTM?

Is LIMN or QNTM more profitable?

Which has higher earnings & valuation, LIMN or QNTM?

Do analysts prefer LIMN or QNTM?

Do institutionals and insiders hold more shares of LIMN or QNTM?

Does the media favor LIMN or QNTM?

Summary

How does Liminatus Pharma compare to Celularity?

Is CELU or LIMN more profitable?

Which has more risk & volatility, CELU or LIMN?

Which has better valuation & earnings, CELU or LIMN?

Does the media refer more to CELU or LIMN?

Do institutionals and insiders have more ownership in CELU or LIMN?

Do analysts rate CELU or LIMN?

Summary

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Do institutionals & insiders have more ownership in NEUP or LIMN?

Which has higher earnings and valuation, NEUP or LIMN?

Which has more volatility & risk, NEUP or LIMN?

Is NEUP or LIMN more profitable?

Do analysts rate NEUP or LIMN?

Does the media refer more to NEUP or LIMN?

Summary

How does Liminatus Pharma compare to AlloVir?

Which has more risk and volatility, ALVR or LIMN?

Do insiders & institutionals have more ownership in ALVR or LIMN?

Is ALVR or LIMN more profitable?

Do analysts recommend ALVR or LIMN?

Which has stronger valuation & earnings, ALVR or LIMN?

Does the media prefer ALVR or LIMN?

Summary

How does Liminatus Pharma compare to Werewolf Therapeutics?

Which has higher earnings & valuation, HOWL or LIMN?

Is HOWL or LIMN more profitable?

Does the media favor HOWL or LIMN?

Which has more risk & volatility, HOWL or LIMN?

Do insiders and institutionals believe in HOWL or LIMN?

Do analysts recommend HOWL or LIMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools